Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
CRBU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.62
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.00M
Market Cap
$93.00M
Enterprise Value-$24.23M
Total Cash (Recent Filing)$16.29M
Total Debt (Recent Filing)$26.49M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
May 13, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding93,004,600
10 Day Avg. Volume943,124
30 Day Avg. Volume1,003,281
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.31
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.42
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$13.00Price Target Upside1150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Caribou Biosciences News
PremiumCompany Announcements
Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges
PremiumCompany Announcements
Caribou Biosciences Advances CAR-T Therapy Trials
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe CaMMouflage Ph1 study of CB-011 in r/r multiple myeloma is escalating to DL4 after clearing DL3 with no dose-limiting toxicities and signs of efficacy.
Cost ManagementR&D and SG&A expenses were below consensus estimates, indicating effective cost management.
Financial StabilityCaribou ended 2024 with $249.4M in cash, cash equivalents, and marketable securities, which is slated to provide a runway into 2H26.
Bears Say
Clinical DelaysPlanned pivotal trial for CB-010 is delayed by at least six months due to a focus on human leukocyte antigen matching.
Clinical RisksRisks include negative clinical results with the company's lead assets and delays in advancing these candidates into registrational programs.
Regulatory ApprovalThe probability of approval for CB-010 has been lowered to 20% from the prior 30% due to the decline in efficacy.
---
Ownership Overview
8.13% Insiders
11.11% Mutual Funds
19.76% Other Institutional Investors
49.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.95 and its highest was $5.62 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $93.00M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is May 13, 2025 which is in 51 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Mar 10, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.027.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.45.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 93,004,600 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went down -2.727%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
---
Caribou Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (1150.00% Upside)
$13.00 (1150.00% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 192.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.19%
12-Months-Change
Fundamentals
Return on Equity
-47.99%
Trailing 12-Months
Asset Growth
-27.24%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
---
CRBU Stock 12 Month Forecast
Average Price Target
$13.00
▲(1150.00% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering CRBU
1 Year
1 Year Success Rate
2/20 ratings generated profit
1 Year Average Return
-45.12%
reiterated a buy rating 5 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -45.12% per trade.
---